Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 8/20 | 0.69 |
| ▸ | PKLR | P30613 | 1/20 | 0.69 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | IL1RN | P18510 | 1/20 | 0.60 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343351 | 1.00 | PKM (0.69) | PKMPKLRCYTH2SMN1; SMN2LMNA | |
| SCHEMBL17849559 | 0.90 | PKM (0.67) | PKMPKLRCYTH2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4955646 | 0.86 | CYTH2 (0.64) | PKMPKLRCYTH2SMN1; SMN2LMNA | |
| SCHEMBL14403177 | 0.86 | PKM (0.71) | PKMPKLRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL30532923 | 0.86 | PKM (0.71) | PKMPKLRSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL14606818 | 0.85 | CYTH2 (0.77) | PKMCYTH2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5800778 | 0.85 | FFAR4 (0.68) | PKMPKLRCYTH2SMN1; SMN2LMNA | |
| SCHEMBL8976245 | 0.85 | PKM (0.67) | PKMCYTH2SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL6574329 | 0.85 | FFAR4 (0.63) | PKMPKLRCYTH2SMN1; SMN2LMNA | |
| SCHEMBL13997280 | 0.85 | CYTH2 (0.71) | PKMPKLRCYTH2SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101108-A1 | METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF CELL SURFACE PD-L1/L2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023091951-A1 | METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF TUMOR CELL SURFACE PD-L1/L2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-25 | — | — | WO | claimed |
| US-20250101108-A1 | METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF CELL SURFACE PD-L1/L2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023091951-A1 | METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF TUMOR CELL SURFACE PD-L1/L2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| CN-101553468-A | Organic compounds | NOVARTIS AG (CH) | 2009-10-07 | — | — | CN | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101108-A1 | METHODS TO ENHANCE THERAPEUTIC EFFICACY IN MELANOMA VIA MODULATION OF CELL SURFACE PD-L1/L2 | PDCD1LG2, ITCH, PDCD1 | PKM 3144/4885PKLR 1403/4885CYTH2 271/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | PKM 981/4885PKLR 881/4885CYTH2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.